Large And Small-Scale Bioprocessing Market Report 2026

Large And Small-Scale Bioprocessing Market Overview

• Large And Small-Scale Bioprocessing market size has reached to $67.66 billion in 2025 • Expected to grow to $119.99 billion in 2030 at a compound annual growth rate (CAGR) of 11.8% • Growth Driver: Surging Demand Of Biologics Fuels Growth In The Large And Small-Scale Bioprocessing Market • Market Trend: Advancements In Compact Fixed-Bed Bioprocessing Systems For Scalable Viral Vector Manufacturing • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Large And Small-Scale Bioprocessing Market?

Large and small-scale bioprocessing are essential components of the biotechnology and pharmaceutical industries that involve using living cells or their components to obtain desired products, such as pharmaceuticals, chemicals, and biofuels. Large-scale bioprocessing refers to the industrial-level production of biological products involving large bioreactors and extensive infrastructure. In contrast, Small-scale bioprocessing consists of the production of biological products on a smaller scale, often for research, development, pilot studies, or niche markets. The main products of large and small-scale bioprocessing are bioreactors or fermenters, cell culture products, filtration assemblies, bioreactor accessories, bags and containers, and others. Bioreactors, or fermenters, are vessels designed to support the growth and metabolic activity of microorganisms or cells under controlled conditions to produce desired biological products. The various modes include in-house and outsourced and have several workflows, mainly downstream processing, fermentation, and upstream processing. These are used on a variety of scales, including industrial scale and small scale, and are utilized in biopharmaceuticals, specialty industrial chemicals, and environmental aids applications.

What Is The Large And Small-Scale Bioprocessing Market Growth Forecast?

The large and small-scale bioprocessing market size is expected to see rapid growth in the next few years. It will grow to $119.99 billion in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to increasing demand for biologics and biosimilars, rising adoption of single-use technologies, growth of personalized and precision medicine, expansion of CDMO services, increasing focus on sustainable bioprocessing methods. Major trends in the forecast period include rising adoption of single-use and modular bioprocessing systems, growing demand for flexible small-scale bioprocessing in R&D, expansion of contract biomanufacturing and outsourcing models, increasing focus on process scalability from lab to commercial scale, rising integration of upstream and downstream bioprocess workflows.

What Is The Driver Of The Large And Small-Scale Bioprocessing Market?

The growing demand for biologics is expected to propel the growth of the large and small-scale bioprocessing market going forward. Biologics refer to medicinal products derived from living organisms or their components, including vaccines, blood and blood components, gene therapies, tissues, and recombinant therapeutic proteins. The growing demand for biologics is due to advancements in biotechnology, increased understanding of disease mechanisms, and the demand for targeted and personalized therapies. Both large-scale and small-scale bioprocessing are integral to biologics' successful development and commercialization. Small-scale bioprocessing is essential for early-stage development, optimization, and feasibility studies. In contrast, large-scale bioprocessing ensures that biologics are produced efficiently, consistently, and in compliance with regulatory standards for commercial distribution. For instance, in February 2024, according to the National Library of Medicine, a US-based medical library, in 2023, the Food and Drug Administration (FDA) approved 55 new drugs, including 29 new chemical entities (NCEs) and 25 new biological entities (NBEs), marking a 50% increase compared to the 37 approvals in 2022. Therefore, the growing demand for biologics drives the growth of the large and small-scale bioprocessing industry.

Key Players In The Global Large And Small-Scale Bioprocessing Market

Major companies operating in the large and small-scale bioprocessing market are F. Hoffmann-La Roche AG, Novartis AG, Sanofi S.A., Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Ltd., Eli Lilly and Company, AbbVie Inc., Amgen Inc., Biogen Inc., Regeneron Pharmaceuticals Inc., Genentech Inc., Gilead Sciences Inc., Novo Nordisk A/S, CSL Limited, UCB S.A., Samsung Biologics, WuXi Biologics, Boehringer Ingelheim

Global Large And Small-Scale Bioprocessing Market Trends and Insights

Major companies operating in the large and small-scale bioprocessing market are focusing on developing innovative solutions, such as fixed-bed, low-footprint bioreactor controllers, to meet the rising demand for high-productivity, cost-efficient, and scalable viral vector and advanced therapy manufacturing driven by the boom in gene therapies, vaccines, and biologics. A fixed-bed, low-footprint bioreactor controller is a specialized hardware module that manages large-area cell culture in fixed-bed reactors, offering a compact form factor, intuitive user interface, and optimized fluid handling in contrast to traditional large-scale stirred-tank bioreactors that demand large physical space, high capital cost, and complex infrastructure. For instance, in May 2025, Univercells Technologies SA, a Belgium-based bioprocessing company, launched the scale-X Nitro Controller, designed to operate their 200 m² and 600 m² scale-X Nitro fixed-bed bioreactors. The controller comes as a compact, wheeled unit (1.6 m² footprint) that fits through standard cleanroom doors, supports both adherent and suspension cultures, and offers highly intuitive control. It enables rapid scale-up from R&D to commercial manufacturing (in ~8 months) while reducing cost-of-goods by 36–82% compared to traditional adherent processes. By combining high productivity with a simplified, space-saving design, the scale-X Nitro Controller helps biomanufacturers especially CDMOs and vaccine developers accelerate their development timelines and lower the economic barrier for large-scale viral production.

What Are Latest Mergers And Acquisitions In The Large And Small-Scale Bioprocessing Market?

In February 2025, Thermo Fisher Scientific Inc., a US-based life-sciences technology company, acquired the Purification & Filtration business of Solventum Corporation for approximately US$ 4.1 billion. With this acquisition, Thermo Fisher aims to strengthen its bioprocessing portfolio by adding Solventum’s advanced filtration and membrane technologies, thereby expanding its biologics manufacturing capabilities across upstream and downstream workflows. Solventum Corporation is a US-based healthcare and materials science company that specializes in purification and filtration technologies for biologics, industrial applications, and medical devices..

What Defines the Large And Small-Scale Bioprocessing Market?

The large and small-scale bioprocessing market consists of revenues earned by entities by providing microbial bioprocessing, plant cell bioprocessing, animal cell bioprocessing, and algal bioprocessing. The market value includes the value of related goods sold by the service provider or included within the service offering. The large and small-scale bioprocessing market also includes sales of incubators, shakers, and cell culture media. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Large And Small-Scale Bioprocessing Market Report 2026?

The large and small-scale bioprocessing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the large and small-scale bioprocessing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.